Compare Johnson & Johnson (JNJ) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Johnson & Johnson trades at $249.41 (market cap $598.96B), while YieldMax Universe Fund of Option Income ETFs trades at $7.72. The key difference: Johnson & Johnson pays a 2.15% dividend while YieldMax Universe Fund of Option Income ETFs pays none, and Johnson & Johnson is trading nearer its 52-week high, YieldMax Universe Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals.
| JNJ | YMAX | |
|---|---|---|
Market Cap | $598.96B | — |
Volume | 6,156,228 | — |
Sector | Health | Income / Options Overlay |
52-Week High | $267.24 | $14.00 |
52-Week Low | $164.36 | $7.51 |
Enterprise Value | $631.90B | — |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
YMAX trades at $7.52 with no recent price movement. Technical indicators show a bearish trend, with moving averages signaling sell pressure and oscillators neutral. The fund generates weekly dividend income, though recent news highlights concerns over fee structures impacting payouts. Support and resistance are tightly clustered around $7 and $8, indicating limited near-term price range.
Outlook remains cautious due to bearish technicals and cost structure headwinds. The high-yield strategy offers income but faces erosion from layered fees. Key risks include dependency on market volatility for strategy success and competitive pressures in the ETF space. Investors should weigh yield against potential capital depreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
